You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 3, March 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

New Reasons for an Archaic Treatment

Phlebotomy in Sporadic Porphyria Cutanea Tarda

Arch Dermatol. 2003;139:379-380.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

SINCE ANTIQUITY, blood extraction (phlebotomy) has been empirically and largely used for many conditions and illnesses because it was thought that blood accumulation was the cause or consequence of the trouble. Galen himself proposed this method for different conditions. But for those who are not in the field of medicine, it could be astonishing that this gory and archaic method is still useful in the beginning of the 21st century.

On the other hand, after the description of the first anecdotal cases, the history of porphyrias is now more than 90 years old. The first basic studies of Günther1 recognized the existence of acute, chronic, and congenital forms. In 1937, Waldenstrom2 identified these diseases as being due to porphyrin metabolism abnormalities, and 17 years later, in 1954, the Minneapolis School3 proposed a classification according to the main organ of the abnormal porphyrin overproduction (liver in hepatic porphyrias and bone marrow . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Hemochromatosis (HFE) Gene Mutations and Response to Chloroquine in Porphyria Cutanea Tarda
Ulrich Stölzel, Erich Köstler, Detlef Schuppan, Matthias Richter, Uwe Wollina, Manfred O. Doss, Christian Wittekind, and Andrea Tannapfel
Arch Dermatol. 2003;139(3):309-313.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Case for Diagnosis
Arch Dermatol 2009;145:12-12.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.